Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia

Haematologica. 2004 Jul;89(7):ECR20.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / metabolism
  • Male
  • Neoplasms, Multiple Primary* / drug therapy
  • Neoplasms, Multiple Primary* / metabolism
  • Piperazines / therapeutic use*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / metabolism
  • Proto-Oncogene Proteins c-kit / biosynthesis
  • Pyrimidines / therapeutic use*
  • Receptors, Platelet-Derived Growth Factor / biosynthesis
  • Signal Transduction / drug effects
  • Testis / metabolism
  • Testosterone / biosynthesis

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Testosterone
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit
  • Receptors, Platelet-Derived Growth Factor